Desmoid Tumors Market Report 2026

Desmoid Tumors Market Overview

• Desmoid Tumors market size has reached to $3.15 billion in 2025 • Expected to grow to $4.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market • Market Trend: Increasing Focus On Drug Developments To Drive The Revenues • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Desmoid Tumors Market?

Desmoid tumors refer to rare non-cancerous (benign) tumors that arise from connective tissue cells, usually in the fascia, which is the tissue that surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means they can grow and invade nearby structures but do not spread to distant parts of the body like traditional cancer. The main treatments for desmoid tumors are surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, and others. Surgery refers to a medical procedure for removing or repairing tissues or organs from the body. It is diagnosed in various ways, such as biopsy, electron microscopic examination, immunohistochemical analysis, and others by hospitals and clinics, specialty centers, and others.

What Is The Desmoid Tumors Market Growth Forecast?

The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to advancements in molecular therapies, growth of rare disease pipelines, increasing clinical trials, improved diagnostic imaging, expanding specialty centers. Major trends in the forecast period include shift toward non-surgical management, rising use of targeted molecular therapies, growth of watchful waiting strategies, expansion of multidisciplinary care models, increased focus on rare disease research.

Global Desmoid Tumors Market Segmentation

1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments 2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis 3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users Subsegments: 1) By Surgery: Wide Excision, Minimally Invasive Surgery 2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy 3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids 4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors 5) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy 6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors 7) By Other Treatments: Watchful Waiting, Physical Therapy, Pain Management Strategies

What Is The Driver Of The Desmoid Tumors Market?

The rising cases of cancer are expected to propel the growth of the desmoid tumor market going forward. Cancer refers to a collection of disorders that are defined by the body's aberrant cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs and cause harm. The rising cancer cases worldwide have fueled the demand for effective and advanced chemotherapeutic agents, positively influencing the desmoid tumor market. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the rising cases of cancer are driving the growth of the desmoid tumor industry.

Key Players In The Global Desmoid Tumors Market

Major companies operating in the desmoid tumors market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Eisai Limited, Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Blueprint Medicines Corporation, Debiopharm Group, Clovis Oncology Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

Global Desmoid Tumors Market Trends and Insights

Major companies operating in the desmoid tumors market are developing innovative drugs such as nirogacestat for the treatment of desmoid tumors to meet the needs of their existing consumers better. Nirogacestat is an oral, small-molecule gamma-secretase inhibitor. For instance, in February 2023, SpringWorks Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced a U.S. Food and Drug Administration (FDA) acceptance and priority review of their new drug application (NDA) for nirogacestat for the treatment of adults with desmoid tumors. Nirogacestat is thought to work by blocking the production of notch proteins, which can lead to the death of tumor cells. Desmoid tumors produce high levels of notch protein, which is thought to contribute to their growth. Moreover, nirogacestat provides patients with a new treatment option that can potentially improve outcomes.

What Are Latest Mergers And Acquisitions In The Desmoid Tumors Market?

In January 2023, Advaxis Inc., a US-based biotechnology company, merged with Ayala Pharmaceuticals Inc. This merger focuses on creating a combined company for developing and commercializing Ayala's lead program, AL102, to treat desmoid tumors. It also aims to accelerate the development and commercialization of AL102 and create a more diversified and robust cancer portfolio. Ayala Pharmaceuticals Inc. is a US-based biotechnology company that is developing AL102, a vaccine candidate for the treatment of desmoid tumors.

Regional Outlook

North America was the largest region in the desmoid tumors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Desmoid Tumors Market?

The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Desmoid Tumors Market Report 2026?

The desmoid tumors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.